Market Access News | pharmaphorum

News

Shionogi takes Akili’s ADHD digital therapy to Japan

Digital health company Akili is on the brink of its first major expansion beyond the US, partnering with Shionogi to file a localised version of its attention deficit hype

News

CHMP backs AZ’s danicopan for anaemia in patients with PNH

AstraZeneca has moved a step closer to EU approval of oral Factor D inhibitor danicopan in the EU, after the EMA’s human medicines committee, the CHMP, backed the drug as

News

Interchangeable high-concentration Humira approved in US

For the first time, pharmacists in the US will be able to substitute a cheaper biosimilar version when they receive a prescription for AbbVie’s high-concentration formulat

News

CSL, Travere close on EU approval of IgAN drug sparsentan

Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy, after getting a positive opinion on the drug from the EM

News

Bavarian Nordic gets swift EU review of chikungunya shot

Bavarian Nordic will get an accelerated review of its chikungunya vaccine CHIKV VLP at the EMA, as it tries to chase down a lead held by rival Valneva.

News

FDA will decide in June on Dupixent for COPD

The FDA has started a priority review of Sanofi and Regeneron’s Dupixent as a treatment for chronic obstructive pulmonary disease (COPD), which could become the first new

Shionogi takes Akili’s ADHD digital therapy to Japan

CHMP backs AZ’s danicopan for anaemia in patients with PNH

Interchangeable high-concentration Humira approved in US

CSL, Travere close on EU approval of IgAN drug sparsentan

Bavarian Nordic gets swift EU review of chikungunya shot

FDA will decide in June on Dupixent for COPD

Bankruptcy threat looms as Quince runs out of options

How to meet your physicians where they are online

News

Editor's Picks